Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
Sponsor: Bayer
This PHASE3 trial investigates Prostatic Neoplasms and is currently completed. Bayer leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Apr 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Donggu, South Korea , Guangzhou, China , Kaohsiung City, Taiwan , Nanjing, China , Seoul, South Korea , Shanghai, China , Singapore, Singapore , Taipei, Taiwan , Taipei City, Taiwan and 1 more location